NICE IDs

04/09/2025

ID5073: Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

03/09/2025

TA1096: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis

28/08/2025

ID6394: Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over

26/08/2025

TA1052:Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)

18/08/2025

ID6212:Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments

14/08/2025

ID6145: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12)

08/08/2025

ID6332: Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable

07/08/2025

ID547: Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over

01/08/2025

ID6266: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis

31/07/2025

ID6381: Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer

22/07/2025

ID2725: Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma

16/07/2025

ID6364: Tarlatamab for previously treated advanced small-cell lung cancer

15/07/2025

ID6462: Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen

14/07/2025

ID6237: Guselkumab for treating moderately to severely active ulcerative colitis

14/07/2025

ID6238: Guselkumab for previously treated moderately to severely active Crohn's disease

11/07/2025

ID3981: Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable

04/07/2025

ID6372: Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over

25/06/2025

ID6274: Fruquintinib for previously treated metastatic colorectal cancer

20/06/2025

ID6392: Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments

19/06/2025

ID6153: Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer